Apollomics Overview
- Year Founded
-
2015

- Status
-
Public
- Employees
-
13

- Stock Symbol
-
APLM

- Investments
-
1
- Share Price
-
$5.45
- (As of Friday Closing)
Apollomics General Information
Description
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Contact Information
Website
www.apollomicsinc.comCorporate Office
- 989 East Hillsdale Boulevard
- Suite 220
- Foster City, CA 94404
- United States
Corporate Office
- 989 East Hillsdale Boulevard
- Suite 220
- Foster City, CA 94404
- United States
Apollomics Timeline
Apollomics Stock Performance
As of 11-Jul-2025, Apollomics’s stock price is $5.45. Its current market cap is $6.29M with 1.1M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$5.45 | $5.70 | $4.47 - $35.98 | $6.29M | 1.1M | 20.2K | -$52.80 |
Apollomics Financials Summary
As of 31-Dec-2024, Apollomics has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | (10,455) | (10,455) | 34,412 | |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (53,539) | (53,539) | (172,525) | (240,373) |
Net Income | (53,858) | (53,858) | (172,601) | (240,811) |
Total Assets | 13,098 | 13,098 | 55,387 | 76,475 |
Total Debt | 966 | 966 | 4,661 | 991 |
Apollomics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Apollomics Comparisons
Industry
Financing
Details
Apollomics Competitors (44)
One of Apollomics’s 44 competitors is AnaptysBio, a Formerly VC-backed company based in San Diego, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
AnaptysBio | Formerly VC-backed | San Diego, CA | ||||
Mersana Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
CalciMedica | Formerly VC-backed | La Jolla, CA | ||||
Altimmune | Corporate Backed or Acquired | Gaithersburg, MD |
Apollomics Patents
Apollomics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240218453-A1 | Diagnostic and treatment of cancer using c-met inhibitor | Pending | 21-Apr-2021 | ||
EP-4162032-A2 | Enzymes and regulatory proteins in tryptamine metabolism | Inactive | 06-Jun-2020 | ||
US-20230338294-A1 | Novel pharmaceutical formulation for c-met inhibitor | Pending | 26-Apr-2020 | ||
US-20200405719-A1 | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint | Inactive | 17-Feb-2018 | ||
US-11111300-B2 | Anti pd-l1 antibodies | Active | 05-Aug-2014 | C07K16/2827 |
Apollomics Signals
Apollomics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Apollomics Acquisitions (1)
Apollomics’s most recent deal was a Merger/Acquisition with Maxpro Capital Acquisition. The deal was made on 29-Mar-2023.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Maxpro Capital Acquisition | 29-Mar-2023 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Apollomics FAQs
-
When was Apollomics founded?
Apollomics was founded in 2015.
-
Where is Apollomics headquartered?
Apollomics is headquartered in Foster City, CA.
-
What is the size of Apollomics?
Apollomics has 13 total employees.
-
What industry is Apollomics in?
Apollomics’s primary industry is Drug Discovery.
-
Is Apollomics a private or public company?
Apollomics is a Public company.
-
What is Apollomics’s stock symbol?
The ticker symbol for Apollomics is APLM.
-
What is the current stock price of Apollomics?
As of 11-Jul-2025 the stock price of Apollomics is $5.45.
-
What is the current market cap of Apollomics?
The current market capitalization of Apollomics is $6.29M.
-
Who are Apollomics’s competitors?
AnaptysBio, Mersana Therapeutics, AnTolRx, CalciMedica, and Altimmune are some of the 44 competitors of Apollomics.
-
What is Apollomics’s annual earnings per share (EPS)?
Apollomics’s EPS for 12 months was -$52.80.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »